Charles Schwab Investment Management Inc Zynerba Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.86 - $2.06 $32,332 - $77,447	37,596 New	37,596 $43,000
Q1 2022 May 13, 2022	SELL	$1.83 - $3.02 $33,110 - $54,640	-18,093 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.83 - $5.98 $69,296 - $108,196	18,093 New	18,093 $96,000
Q2 2020 Aug 14, 2020	SELL	$3.31 - $6.54 $189,772 - $374,957	-57,333 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$7.56 - $15.44 $35,116 - $71,718	4,645 Added 8.82%	57,333 $434,000
Q2 2019 Aug 09, 2019	BUY	$5.4 - $15.5 $284,515 - $816,664	52,688 New	52,688 $714,000
Q2 2018 Aug 08, 2018	SELL	$7.98 - $12.39 $153,216 - $237,888	-19,200 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$5.73 - $9.44 $110,016 - $181,248	19,200	19,200 $161,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.